galcanezumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
galcanezumab: clinical details
Prescribing considerations
- Initiation should be by a physician experienced in diagnosing and treating migraine.
- Document baseline migraine burden and reassess clinical benefit regularly.
- Safety data are lacking in people with certain major cardiovascular diseases because these groups were excluded from clinical studies.
- Safety and efficacy have not been established in children or adolescents, and experience in older adults is limited.
Contraindications and cautions
- Hypersensitivity to galcanezumab or any formulation excipient.
Monitoring
- Monitor effectiveness using a consistent record of migraine and headache burden.
- Counsel about immediate and delayed hypersensitivity and discontinue promptly if a serious reaction occurs.
- Record the product name and batch number to support biological-medicine traceability.
- Review constipation, vertigo, injection-site reactions and other suspected adverse effects.
Clinical pharmacology
Galcanezumab is a humanised IgG4 monoclonal antibody that binds circulating CGRP rather than its receptor. It is expected to be broken down through catabolic pathways into peptides and amino acids, making conventional metabolic pharmacokinetic interactions unlikely.
Formulation and product differences
- The selected product is a clear, colourless to slightly yellow solution in a disposable, single-use pre-filled pen.
- Available pack sizes may vary, and not every authorised pack is necessarily marketed.
galcanezumab preparations and strengths
Injection
Route: Parenteral
Strengths: 120 mg
galcanezumab interactions
Formal interaction studies have not been conducted, but pharmacokinetic interactions are not expected. The prescriber should still review all medicines and supplements.
Other monoclonal antibodies
No specific interaction is established, but combination experience may be limited, so relevant specialists should review suitability.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.